Indian Panel's Price Ceiling Reference Baffles Device Firms
In a rather odd move, a key Indian expert panel concerned with trial-related approvals has outlined pricing restrictions in the device space, keeping industry on tenterhooks about potential implications, if any. The move comes after recent price-cap plans were announced in the segment.
You may also be interested in...
Innovator firms will need more than just sharp business strategies to tap into the high potential but fluid pharmaceutical markets in the BRIC/MIST countries (Brazil, Russia, India, China, Mexico, Indonesia, South Korea, and Turkey). Flexibility well beyond pricing and the ability to wait it out till the rewards creep in are vital in these markets.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.